Abstract Oculoskeletal dysplasia segregates as an autosomal recessive trait in the Labrador retriever and Samoyed canine breeds, in which the causative loci have been termed drd1 and drd2, respectively. Affected dogs exhibit short-limbed dwarfism and severe ocular defects. The disease phenotype resembles human hereditary arthroophthalmopathies such as Stickler and Marshall syndromes, although these disorders are usually dominant. Linkage studies mapped drd1 to canine chromosome 24 and drd2 to canine chromosome 15. Positional candidate gene analysis then led to the identification of a 1-base insertional mutation in exon 1 of COL9A3 that cosegregates with drd1 and a 1,267-bp deletion mutation in the 5 0 end of COL9A2 that cosegregates with drd2. Both mutations affect the COL3 domain of the respective gene. Northern analysis showed that RNA expression of the respective genes was reduced in affected retinas. These models offer potential for studies such as protein-protein interactions between different members of the collagen gene family, regulation and expression of these genes in retina and cartilage, and even opportunities for gene therapy.
Introduction
Oculoskeletal dysplasia (OSD) in Labrador retriever (Carrig et al. 1997) and Samoyed (Meyers et al. 1983 ) dogs causes skeletal abnormalities, including short-limbed dwarfism, and ocular defects, including vitreous dysplasia, retinal detachment, and cataracts, and segregates as an autosomal recessive trait in both breeds. Obligate heterozygotes may exhibit a mild ocular phenotype ranging from vitreal strands, or localized retinal dysplasia characterized by focal or multifocal retinal folds, to large plaques of dysplastic retinal tissue, but they have a normal appendicular skeleton. Previous studies have established that these two disorders are nonallelic (Acland and Aguirre 1995; Du 2000) and the two loci have been termed drd1 (dwarfism with retinal dysplasia type 1, Labrador retriever) and drd2 (dwarfism with retinal dysplasia type 2, Samoyed), respectively. The oculoskeletal phenotype in these dogs resembles human hereditary arthro-ophthalmopathies such as Stickler syndrome (Stickler et al. 1965) , Kniest dysplasia (Maumenee and Traboulsi 1985) , and Marshall syndrome (Ayme and Preus 1984) . There is considerable overlap, phenotypic variability, and genetic heterogeneity among these human disorders. Most commonly, however, for those human patients whose phenotype includes vitreous lesions, the trait is dominantly inherited and associated with mutations in the gene for collagen type II (COL2A1) or, less frequently, COL11A1 (Snead and Yates 1999 ). An autosomal recessive form of Stickler syndrome has been associated with an R295X mutation in COL9A1 in one human family (Van Camp et al. 2006 ). More commonly, however, mutations in the collagen type IX genes (COL9A1, COL9A2, COL9A3) have been implicated in dominantly inherited human multiple epiphyseal dysplasias without ocular involvement. COL2A1 was previously excluded as a candidate for OSD in both breeds despite a severe decrease of its protein in the vitreous of OSD-affected Labrador retrievers . Collagen types XI (COL11A1, COL11A2) and V (COL5A2), Vitrin (Du 2000) , and Opticin (Pellegrini et al. 2002) were also excluded previously. In the present study, a genome-wide scan of OSD-informative pedigrees mapped drd1 and drd2 to canine chromosomes 24 (CFA24) and 15 (CFA15), respectively. Positional candidate gene analysis identified a COL9A3 mutation cosegregating with drd1 and a COL9A2 mutation cosegregating with drd2.
Materials and methods

Study animals
Colony dogs
The drd1 and drd2 strains of dog are part of an NIHsponsored project (EY006855) at the Retinal Disease Studies Facility (RDSF) in Kennett Square, PA. The drd1 strain was derived from two OSD-affected unrelated Labrador retriever dogs (Fig. 1a , dogs 2 and 4) that were bred to unrelated crossbred dogs. Their heterozygous F1 progeny were then backcrossed to drd1-affected dogs or intercrossed to drd1 carriers to yield litters segregating the drd1 phenotype. The drd2 strain was similarly derived from one OSD-affected Samoyed (Fig. 1b, dog 2) . Altogether, 150 such colony-derived dogs were studied, including 80 Labrador retriever-derived ( Fig. 1a) and 70 samoyedderived dogs (Fig. 1b) . Eight drd1-informative families included five intercross breedings with 50 progeny and 
Pedigreed dogs
Nondwarf dogs within each OSD-affected breed were screened for the mutations: 118 Labrador retrievers (88 of normal phenotype, 22 with clinically diagnosed retinal folds, and 8 diagnosed with dwarfism) were tested for the COL9A3 mutation and 61 Samoyeds were tested for the COL9A2 mutation (Supplementary Table 2A , B). Privately owned pedigreed dogs from breeds not known to segregate OSD were screened for the mutations included 81 dogs from 22 breeds tested for the COL9A3 mutation and 118 dogs from 23 breeds tested for the COL9A2 mutation (Supplementary Table 2C ). Fourteen dogs from five breeds considered to be phenotypically dwarf as a breed characteristic were also tested for both mutations (Supplementary  Table 2D ).
Phenotypic evaluation of study dogs
Assignment of OSD phenotype was based on clinical, ophthalmoscopic, and morphologic examination. Dogs from experimental pedigrees were examined ophthalmoscopically at approximately 8 and 12 weeks postnatal age. In selected cases, dog retinal tissues were collected postmortem for light microscopy. Evaluation of skeletal phenotype was based on physical examination at 8 and 12 weeks postnatal age and, in selected cases, by radiography. Dwarf dogs not retained for breeding purposes were euthanized and their skeletal phenotype confirmed at necropsy. All procedures involving animals were performed in accordance with the Association for Research in Vision & Ophthalmology (ARVO) Resolution for the use of Animal in Research.
DNA and RNA extraction DNA was extracted from whole-blood and spleen samples as previously described (Goldstein et al. 2006) . Retinal samples from colony dogs were frozen in liquid nitrogen immediately after euthanasia in RNase-free conditions and stored at -70°C until used. Total RNA was extracted from retinas from a 7.6-week-old drd1-affected dog, a 12-weekold drd2-affected dog, and three homozygous normal dogs (4, 7, and 10 weeks old), using Trizol (Invitrogen, Carlsbad, CA) following the manufacturer's protocol and protected with RNase inhibitor (Roche Applied Science, Roche Diagnostics, Indianapolis, IN).
Whole-genome scan and linkage analysis A genome-wide scan on drd1 and drd2 informative pedigrees (Fig. 1a, b ) was undertaken using a 249-microsatellite canine marker set (Mammalian Genotyping Service, Marshfield, WI) as previously described (Kukekova et al. 2006) . Linkage analysis of genotypes passing Marshfield quality control was undertaken separately for the two breed-specific pedigrees using MultiMap (Kukekova et al. 2006; Matise et al. 1994) , with phenotype scored as follows: normal outbred dogs 2,2; dwarf dogs 1,1; obligate heterozygotes (e.g., nondwarf dogs in back-cross litters) 1,2; and nondwarf dogs in intercross litters as either 0,0 if no ocular lesions were observed or as 1,2 if retinal folds and/or vitreal strands were detected. Regions of the dog genome identified by two-point linkage analysis with LOD [ 3 were further investigated. Marker order on chromosomes that showed linkage to the diseases was determined using multipoint analysis; data from both drd1-and drd2-derived colony dogs were used, assigning each breed as control for the other. Comprehensive maps of CFA15 and CFA24 were built at LOD 2 support. Haplotypes for CFA24 and CFA15 were analyzed for drd1 and drd2 pedigrees, respectively, using Cyrillic (Exeter Software, Setauket, NY), given the multipoint marker order. Further linkage analyses were undertaken using LINKAGE (Lathrop et al. 1984) .
Candidate gene screening cDNA was synthesized from normal and drd1-and drd2-affected retinal RNA using a Thermoscript RT-PCR kit (Invitrogen) with oligo-dT. Primers were designed from the CanFam1 (July 2004) Table 3D ). To retrieve the correct 5 0 end of the genomic region of COL9A2 in an unaffected dog, primers from consensus sequences between CanFam1 and CanFam2 were used (Supplementary Table 3E ). To find the deletion in COL9A2 in drd2-affected dogs in that region, genomic primers were designed based on the newly corrected sequence (Supplementary Table 4 ).
RNA expression analysis
RNA membranes containing total RNA from normal, drd1-affected, and drd2-affected retinas were generated as previously described (Goldstein et al. 2006) . COL9A3 and COL9A2 probes were produced by amplification of cDNA using primer pairs 1 and 16 in Supplementary Table 3, respectively, cloned (TOPO TA cloning kit, Invitrogen, CA), and used for blot hybridization. Hybridization was carried out using Ultrahyb solution (Ambion, Austin, TX) following the manufacturer's protocol. Blots were exposed to X-ray film at -70°C for 1-4 days with two intensifying screens. Loading control was achieved by hybridizing a canine-specific b-actin probe to the membranes under the same conditions and exposed to X-ray film for 4 h.
COL9A2 and COL9A3 mutation screening in the population
COL9A3 mutation screening
To identify drd1-affected, drd1-carrier, and normal dogs, genomic DNA was amplified using a primer pair flanking the mutation (Supplementary Table 5 , primer pair 1). Reaction was carried out with 5% DMSO at an annealing temperature of 64°C. PCR products were treated with ExoSAP-IT (USB) for 15 min at 37°C, followed by inactivation at 80°C for 15 min, or they were purified with the PCR purification kit (Qiagen) and sequenced with the forward primer. Alternatively, genotyping was performed using an allele-specific extension method using forward primers specific for each allele (Supplementary Table 5 , primers 2 and 3). Both wild-type and mutant primers contain a mismatch in the 3 0 penultimate base. Primer pair 2 will amplify a 72-bp product from DNA of homozygous wildtype (normal) dogs but will not produce a product from affected dogs, while primer pair 3 will produce a 73-bp product from affected dogs but no product from normal dogs. Carrier dogs will produce products in both PCR reactions. PCR reactions were carried out at 58°C with 11% DMSO and analyzed by electrophoresis on a 6% PAGE.
COL9A2 mutation screening
To identify drd2-affected, drd2-carrier, and normal dogs, two sets of primer pairs were designed and used in two separate PCR reactions (primer pairs 4 and 5 in Supplementary Table 5 ). The annealing temperature was 58°C for primer pair 4 and 60°C for primer pair 5. Primer pair 4 amplifies a 1,445-bp product from homozygous normal samples and a 178-bp product from affected dogs. Although heterozygous (carrier) dogs have both alleles, PCR of their DNA samples using primer pair 4 yields only the smaller product under the conditions used. Therefore, a second PCR reaction was designed using primer pair 5 to yield a 504-bp product from the normal allele, but it yielded no product from the mutated allele because the reverse primer binds within the deletion. PCR products were visualized on a 1.8% agarose gel stained with ethidium bromide using standard protocols.
Results
Phenotypic evaluation
In litters informative for either drd1 or drd2, affected (dwarf) pups were distinguishable from their nondwarf littermates from approximately 4-6 weeks postnatal. The earliest and most easily recognized sign was excessive doming of the cranium, with a more pronounced facial stop and moderate exotropic strabismus. Foreshortening, curvature, and varus/valgus deformity of the forelimbs became evident shortly thereafter. Ophthalmoscopic examination revealed a range of defects, the most consistent of which were radial cortical equatorial cataracts and vitreal liquefaction. Complete retinal detachments were frequently present at the first ophthalmoscopic examination, which took place at approximately 6 weeks; if not present at that time, they usually developed subsequently. Retinal detachments and cataracts were not observed in nondwarf dogs in OSD-informative litters examined ophthalmoscopically. In Labrador retrieverderived OSD-informative litters, retinal folds and/or vitreal abnormalities, including partial vitreal liquefaction, and condensed vitreal strands were observed in a minority of nondwarf dogs (15 of 38). Among these, 2 of 13 obligate heterozygotes had retinal folds observed between 6 weeks and 3 months of age while 11 were ophthalmoscopically normal. Similarly, in samoyed-derived OSD-informative litters, although some drd2-obligate heterozygotes had retinal folds, others were ophthalmoscopically normal. Among nondwarf dogs from intercrosses, 24 subsequently genotyped as drd2 carriers, of which 20 had retinal folds and 4 did not.
Genome-wide scan and linkage analysis
Quality control analysis of genotypes returned from Marshfield Laboratories (249 markers 9 150 samples) excluded data representing nine markers (for all samples) and seven dogs (4 from drd1 and 3 from drd2 pedigrees). From drd1-informative Labrador-derived pedigrees, a maximum LOD score of 2.225 at h = 0.19 was achieved on CFA24 for marker FH2079 when nonaffected dogs, i.e., nondwarf dogs from intercrosses, were designated as having unknown status (Table 1a , linkage analysis I); a higher LOD score of 3.589 was obtained at h = 0.142 when all unaffected dogs were designated as drd1 carriers (heterozygotes) (Table 1a , linkage analysis II). The order of the CFA24 markers and relative position of the drd1 locus were established by multipoint linkage analysis with LOD 2 support. Five markers were mapped to unique positions and the order of mapped markers was in agreement with CanFam2. The drd1 locus mapped to the telomeric end of CFA24, 12 cM distal to FH2079. The order of CFA24 markers established by haplotype analysis of drd1-informative pedigrees was in agreement with that identified by multipoint analysis. Haplotype analysis identified 13 affected dogs as recombinant between FH2079 and the disease locus (data not shown), confirmed the mapping of the drd1 locus achieved by multipoint analysis, and suggested that drd1 was most likely located telomeric to FH2079 in the interval CFA24: 39,338,870-tel.
For drd2-informative samoyed-derived pedigrees, a maximum LOD score of 16.461 was obtained on CFA15 with marker REN06C11 at h = 0.031 (Table 1b , linkage analysis IV). Multipoint analysis assigned drd2 to the centromeric end of CFA15, proximal to REN06C11 with h = 0.0. The relative order of five markers mapped on CFA15 and drd2 was established by multipoint analysis. Four CFA15 markers and the drd2 locus mapped to unique positions with LOD 2 support, and the order of mapped markers was in agreement with CanFam2. Marker FH3802 was of low informativeness in samoyed-derived pedigrees and was not assigned to a unique map position. On CanFam2, FH3802 is located centromeric to REN06C11. The drd2 locus was assigned to the centromeric end of These mapping results strongly suggested COL9A3 on CFA24 (49, 700, 713, 993) and COL9A2 on CFA15 (5,651,564-5,665,086) as positional candidates for drd1 and drd2, respectively, as they code for collagen proteins of both cartilage and vitreous, like other genes previously implicated in human oculoskeletal dysplasias, including COL9A1 with which these proteins form heterotrimers.
Candidate gene evaluation
Evaluation of COL9A3 as a candidate gene for OSD in Labrador retrievers Canine COL9A3 mRNA The human COL9A3 gene (NM_001853.2) has 32 exons and is 2,511 bp long. Blasting this sequence against CanFam2 identified 29 of the predicted canine exons but it failed to identify exons 16, 17, and 32. Thirteen primers were designed from the CanFam2 sequence to amplify 11 different overlapping cDNA fragments covering the complete canine COL9A3 coding sequence (Supplementary Table 3A , primer pairs 1-11). A 3 0 -UTR primer was designed from CanFam2 sequence downstream to the gap where exon 32 is presumably located.
Canine COL9A3 fragments were amplified successfully from normal retinal cDNAs and the products were sequenced. A consensus sequence for canine COL9A3 mRNA (accession No. GU075882, Supplementary Fig. 1A ) was assembled using Sequencher (Gene Codes Corp., Ann Arbor, MI, USA). The structure of the canine mRNA is identical to that of human mRNA NM_001853.3 (Fig. 2a) .
Comparison of the predicted protein to human COL9A3 (NP_001844.3) also suggests a completely identical structure.
RACE was undertaken to determine the 5 0 and 3 0 ends of the transcript using gene-specific primers. 3 0 RACE identified two polyadenylated transcripts: one extended 458 bp after the stop codon and included a polyadenylation signal preceding the start of the poly-A tail by 11 bases; the second extended 591 bp after the stop and included a polyadenylation signal preceding the poly-A tail by 16 bases (Supplementary Fig. 1A ). The corresponding genomic 3 0 end of the gene had no such stretches of adenosine. These products were further validated by RT-PCR of cDNA from unaffected retina using a forward primer located on exon 26 and two reverse primers, each located just upstream to the poly-A tail (primer pairs 27 and 28 in Supplementary Table 3 for the short and long transcripts, respectively). The 5 0 RACE experiments failed presumably because of GC richness in the 5 0 end of this transcript. Four single nucleotide polymorphisms (SNPs) were found in the normal transcript within the coding sequence, none of which cosegregates with the disease: G/A in exon 4 (silent), G/A in exon 5 (arginine/glutamine), C/T in exon 28 (silent), and A/G in exon 31 (silent) (nucleotides 49, 702, 320; 49, 702, 704; 49, 712, 359; and 49, 713, 957, respectively, in CanFam2) . Seven more SNPs were identified in the 3 0 UTR (Supplementary Fig. 1A ). Evaluation of COL9A3 in drd1-affected Labradors To evaluate COL9A3 in drd1 disease, retinal cDNA from a 7.6-week-old drd1-affected dog was amplified. Sequence Fig. 2 Schematic illustrations of COL9A3 (a) and COL9A2 (b) mRNAs and their corresponding protein domains. Shaded areas in the mRNA correspond to the COL domains in the protein, unshaded to NC domains. Gray arrows indicate binding sites of primers used to amplify the cDNA. In a, the diamond symbol and the pound symbol indicate the location of the drd1 COL9A3 insertional mutation in exon 1 (c.7-10 insG) and its resulting premature stop codon at amino acid 49 (pA4GX46) in the putative protein, respectively. In b, the dashed black arrow indicates the location of the drd2 COL9A2 mutation (deletion of exon 1) of the PCR products revealed a 1-base insertion (guanine) in exon 1 that changes a string of four guanines (CFA24: 49,699,847-49,699,850; CanFam2) to a string of five guanines (c. 7-10 insG). This shifts the open reading frame of the putative protein, alters amino acids 4-48, and introduces a premature stop codon at codon 49 (p.A4GX46). This insertion is in linkage disequilibrium with a G-G-T-A haplotype corresponding to the four SNPs found in the coding region (Supplementary Fig. 1B ).
Evaluation of COL9A2 as a candidate gene for OSD in the samoyed Canine COL9A2 mRNA The human COL9A2 gene (NM_001852.3) has 32 exons and is 2,831 bp long. Blasting this sequence against CanFam2 identified 30 predicted exons but failed to identify exons 1 and 26. Alignment of NM_001852.3 against the CanFam1 assembly identified a predicted exon 1 and a canine expressed sequence tag (EST) (DN364641) to support this prediction, but it did not identify exons 26 or 32. Ten primer pairs were designed based on the CanFam1 and CanFam2 assemblies to amplify overlapping cDNA fragments covering the complete coding sequence of canine COL9A2 (Supplementary Table 3B ). All ten successfully amplified the expected target fragments from retinal cDNA of normal dogs aged from 4 to 12 weeks old. PCR products were sequenced and the canine COL9A2 mRNA was assembled using Sequencher software (accession No. GU075881, Supplementary Fig. 1C ). The structure of this canine mRNA was highly similar to the human mRNA sequence NM_001852.3 (Fig. 2b) . The length of each exon was identical to that of the corresponding human exons, including the junction exons (i.e., exons that are junctional between the NC and COL domains), except that canine exon 1 is 12 bp shorter than the human exon and encodes only 21 amino acids compared to 25 in human. The predicted canine protein is thus very similar to the human with four noncollagenous domains (NC1-4) and three collagenous domains (COL1-3) (Fig. 2b) , except that the canine NC4 domain has 22 amino acids compared to 26 in human (NP_001843.1).
RACE was undertaken to determine the 5 0 and 3 0 ends of the normal transcript using gene-specific primers. 3 0 RACE identified one transcript. It extended 587 bp after the stop codon and included a polyadenylation signal of 30 bp preceding the start of the poly-A tail. This sequence is missing from both CanFam1 and CanFam2. To validate the authenticity of the poly-A tail, genomic DNA from several normal dogs was amplified using primers located in sequence flanking both sides of the gap (primer pairs 29-31, Supplementary Table 3D) to retrieve the missing sequence (accession No. GU075880). The absence of a polyadenosine stretch from the sequenced products was taken as a validation of the 3 0 RACE product. Further conformation was based on RT-PCR amplification of normal retinal cDNA using a forward primer located on exon 27-28 and reverse primers located just upstream to the poly-A tail (primer pairs 24-26, Supplementary Table 3D ). The 5 0 RACE experiments failed, presumably because of the GC richness of the 5 0 end of this transcript. Establishing the 5 0 genomic sequence of canine COL9A2 Comparison of CanFam1 and CanFam2 revealed differences in the 5 0 end, exon 1, and intron 1 of COL9A2 between the two assemblies. Forward primers were designed based on 5 0 end sequence shared between the two assemblies, reverse primers were designed from intron 2 of the gene, and further primers were subsequently designed based on newly derived sequences to cover the entire region (primer pairs 32-39, Supplementary Table 3E) . Genomic DNA from a nonaffected dog was amplified and the correct sequence determined (accession No. GU075879, Supplementary Fig. 2D ) as similar but not identical to that in CanFam1.
Evaluation of COL9A2 in drd2 The COL9A2 gene was amplified from retinal cDNA from a 12-week-old drd2-affected dog. Except for exon 1, the gene amplified successfully and showed only one difference from the normal mRNA sequence: a polymorphism (C/T transition) in exon 3 (Chr 15: 5, 652, 893, CanFam2) , with the C allele homozygous in all drd2-affected individuals. This SNP changes an amino acid (proline [ serine) but is not causally associated with disease because the C allele was also observed homozygously in dogs not affected with OSD. Because cDNA amplification failed for primer pairs 12, 13, and 14 (Supplementary Table 3B ), a sequence difference was suspected in the 5 0 end of the gene in affected dogs. Once the correct sequence for the 5 0 end of the region was established from an unaffected animal, primers were designed to amplify (1) the genes ZNF643 and SMAP1L that are in proximity to COL9A2, from both retinal cDNA and genomic DNA (Supplementary Table 4 , primer pairs 1-5); (2) the approximately 31-kb region between SMAP1L and COL9A2 exon 2 in 11 distinct amplicons evenly distributed (Supplementary Table 4 , primer pairs 6-21); and (3) exon 2 of COL9A2 and its flanking donor-acceptor sites (Supplementary Table 4 , primer pair 22).
Genomic sequence of COL9A2 exon 2 revealed no differences between drd2-affected and normal DNA, including the splice acceptor site of intron 1 and splice donor site of intron 2. Two genes (SMAP1L, ZNF643) located 5 0 to COL9A2, amplified successfully from both normal and affected retinal cDNA, suggesting that the mutation does not involve these regions. Six of the 11 primer pairs designed to amplify fragments located between SMAP1L and intron 2 of COL9A2 yielded identically sized products from normal and affected substrates. Five pairs, however, yielded different results for affected compared to normal samples: primer pairs 15 and 17 failed to amplify an affected product, and amplicons from pairs 16, 18, and 19 were smaller for affected compared to normal. Sequence analysis of these products revealed a 1,267-bp deletion in affected dogs. This deletion included all of exon 1 and parts of both the 5 0 UTR and intron 1 ( Supplementary  Fig. 1D ).
Segregation evaluation and population study
OSD in drd1
To identify drd1-affected, drd1-carrier, and normal dogs in the Labrador-derived pedigrees and confirm cosegregation of the COL9A3 mutation with the disease, genomic DNA of the 80 Labrador-derived dogs used in the linkage analysis were amplified using primers flanking the mutation (see Methods, Fig. 3a, Supplementary Fig. 2A ). Sequencing of the resulting amplicon with the forward primer identified normal animals (4 Gs) or affected animals (5 Gs), while an overlapping sequence was observed at the insertion point in chromatograms from carrier dogs. All outbred normal dogs were homozygous for the 4 Gs haplotype, all affected dogs were homozygous for the insertion (5 Gs), and all obligate drd1 heterozygotes were heterozygous for the insertion (producing overlapping chromatograms). Of the 30 nonaffected dogs in intercross litters, 5 were genotyped homozygous normal (4 Gs) and 25 were genotyped heterozygous for the insertion (Supplementary Table 6A ). Because all 30 dogs had been scored as carriers in the previous MultiMap analysis, twopoint analysis was rerun to measure linkage between the mutation and the disease phenotype. That gave a LOD score of 25.889 at h = 0.0 (Table 1a , linkage analysis III). This was confirmed by analysis using LINKAGE, which yielded a LOD score of 18.72 at h = 0.0.
One hundred eighteen Labrador retriever dogs were tested for the COL9A3 mutation (Supplementary  Table 2A ). Eighty-eight of these were phenotypically normal, 22 had retinal folds or vitreous abnormalities but were reportedly normal skeletally, six were dwarfs with retinal degeneration, and two were dwarfs with no known retinal abnormalities. Of the 88 phenotypically normal Labradors, 81 genotyped homozygous normal and seven were carriers (heterozygous for the COL9A3 mutation). Of the 22 non-dwarf Labradors that had retinal folds, 21 genotyped homozygous normal and one was a carrier. Of the six Labradors that were dwarf with retinal degeneration, five were homozygous for the mutation and one was homozygous normal. Both Labradors that were dwarf without known retinal abnormalities were also homozygous normal. Although some of the dogs in each category were related to each other, a rough calculation estimates the mutant allele frequency at about 4% but more Labrador retrievers need to be screened to get a more accurate estimation. Ninety-five dogs from 27 additional breeds not recognized as segregating OSD were also screened either by sequencing or by allele-specific extension assay; among them were 14 dogs from five breeds considered to be dwarf breeds. All 95 dogs proved homozygous wild-type at the COL9A3 locus (Supplementary  Table 2C , D). drd2 (b) . a Chromatograms of normal, drd1-carrier, and drd1-affected dogs. Four guanines are observed in the normal sequence, five in affected, and overlapping peaks are observed in sequence from a carrier dog representing the two alleles. b1 A subset of the colony pedigree used for the linkage analysis. b2 PCR product from the drd2 COL9A2 mutant allele on a 1.8% agarose gel. b3 PCR product from the COL9A2 normal allele on a 1.8% agarose gel. A normal dog (dog number 13) yields only the normal allele product, affected dogs (numbers 2, 7, 8) only the mutant product, and carrier dogs (remainder) yield both
OSD in drd2
To identify drd2-affected, drd2-carrier, and normal dogs in the samoyed-derived pedigrees and confirm cosegregation of the COL9A2 mutation with the disease, genomic DNA of the 70 samoyed-derived dogs used in the linkage analysis was amplified using primer pairs designed for screening (see Methods, Fig. 3 , and Supplementary  Fig. 2B ). Analysis of the PCR products showed that all outbred normal dogs were homozygous wild-type, all affected dogs were homozygous for the deletion, and all drd2-obligate heterozygotes were heterozygous for the deletion. The 29 unaffected dogs from intercross litters genotyped as follows: 25 as carriers (23 of which had been scored 1,2 in the MultiMap analysis, one scored 2,2, and one not used), and four as normal (two not used and two scored 2,2), (Supplementary Table 6B ). Two-point analysis to measure linkage between the mutation and the disease phenotype gave a LOD score of 23.179 at h = 0.0 (Table 1b , linkage analysis V).
Sixty-one pedigreed samoyed dogs were screened for the deletion using the above screening test. Fifty-five were unrelated dogs of which one was identified as a carrier of the deletion. Six relatives of this dog were then tested of which one was also identified as a carrier. The affected allele frequency is thus very roughly estimated at about 1% (0.01) in the samoyed population. Another 132 dogs from 28 additional breeds not recognized as segregating OSD were screened for the deletion, including 14 dogs from five breeds considered to be dwarf breeds; all were homozygous wild-type (Supplementary Table 2C, D) .
RNA expression analysis RNA expression was evaluated by Northern blot assay to determine COL9A3 mRNA transcript size and level of expression in drd1-affected retina compared to normal. Northern blot analysis showed one COL9A3 transcript (approximately 3.0 kb) in drd1-nonaffected retina (Fig. 4a,  lanes 1 and 3) , which was absent in a 7.6-week-old drd1-affected retina (Fig. 4a, lane 2) . The same retina did express COL9A2 (Fig. 4b, lane 2) , which suggests that the absence of the COL9A3 mRNA is due not to cell death but rather to other regulatory mechanisms such as nonsensemediated decay.
COL9A2 expression was similarly compared between drd2-affected and normal retina. Two COL9A2 transcripts were observed in drd2-nonaffected retinas, approximately 3.0 and 3.8 kb long (Fig. 4b, lanes 1 and 2) . Both bands were absent from a 12-week-old drd2-affected retina (Fig. 4b, lane 3) . The same affected retina showed expression of COL9A3 (Fig. 4a, lane 3) , suggesting that the absence of the COL9A2 mRNA is due not to cell death but to other regulatory mechanisms. The low mRNA expression levels may result from loss of promoter elements in the 5 0 region of the gene deleted in the mutant allele, as well as from nonsense-mediated decay.
Retinal folds and OSD correlation
Folds and COL9A3 mutation correlation in nonaffected dogs
Since folds were observed in some but not all nondwarf Labrador-derived colony dogs, we tested whether folds and the COL9A3-mutated allele were associated or independent events. Nondwarf dogs were scored for carrier or normal genotype, and folds or no-folds phenotype, in a 2 9 2 table, which when evaluated by Fisher's exact test yielded a two-tailed P value of 1.0. The same test was undertaken to compare the observed phenotypes and genotypes of nondwarf purebred Labrador retrievers, with the same result (P = 1.0). Thus, there is no support for a causal association between the retinal folds phenotype and the mutant COL9A3 allele in these dogs.
Folds and COL9A2 mutation correlation in nonaffected dogs
Comparison of ocular phenotypes of the nondwarf Samoyed-derived colony dogs from intercrosses with their . One band, approximately 3.0 kb in size, is observed. In drd1-affected retina, COL9A3 is at undetectable levels (lane 2). b COL9A2 is expressed in the retina of a dog not affected with OSD (6.9 weeks old, lane 1) and in drd1-affected retina (7.6 weeks old, lane 2). Two bands, approximately 3.0 and 3.8 kb long, are observed. In drd2-affected retina, COL9A2 is at undetectable levels (12 weeks old, lane 3). b-actin was used as a loading control genotype (Supplementary Table 6B ) yielded a Fisher exact test P value of 0.0034 when the phenotype was scored for folds only, and a P value of 0.00073 when the phenotype was scored for folds and/or vitreal membranes/vitreal degeneration. This does lend some support to the possible association between the COL9A2 mutation in the heterozygous state and the folds and/or vitreal membranes phenotype in colony-derived drd2 dogs, but further screening in the purebred samoyed population is needed to evaluate this association further.
Discussion
In humans, COL9A2 and COL9A3 mutations have been associated with multiple epiphyseal dysplasia (MED for COL9A2 mutation and EDM2 and EDM3 for COL9A3 mutation) (Bonnemann et al. 1999; Fiedler et al. 2002; Holden et al. 1999; Lohiniva et al. 2000; Nakashima et al. 2005a, b; Paasilta et al. 1999; Takahashi et al. 2006) . MED is one of the more common forms of human skeletal dysplasia, characterized by a delay in the appearance of the epiphyses, irregular epiphyseal formation, mild short stature, and earlyonset osteoarthritis (Spranger et al. 2002) . All known human mutations to date cause exon 3 skipping, resulting in the predicted consequence of a 12-amino-acid deletion within the COL3 domain of the alpha2(IX) and alpha3(IX) chains. One MED-affected human was heterozygous for a COL9A1 splice-site mutation (Czarny-Ratajczak et al. 2001 ) that resulted in an in-frame deletion of exon 8 and/or exon 10 and an in-frame deletion of 25, 21, or 46 amino acids in the COL3 domain of the alpha1(IX) chain. Since COL9A1 contains six additional exons compared to COL9A2 and COL9A3, exon 9 of COL9A1 corresponds to exon 3 in the other two COL9 genes. This remarkable consistency of type IX collagen mutations clearly suggests that the COL3 domain is of critical functional importance in type IX collagen. It has been suggested that deletions in the COL3 domain disrupt interaction with other components or that the orientation of the NC4 domain relative to type II/XI collagen fibril is changed by the COL3 mutations (Van Camp et al. 2006 ).
Here we reported mutations in the COL3 domain of COL9A2 and COL9A3 associated with OSD in samoyed and Labrador retriever dogs, respectively. In drd1-affected Labradors, the mutation is an insertion of a guanine in exon 1, causing a ?1 frame-shift, altering amino acids 4-48, introducing a premature stop codon, and truncating the predicted protein. In drd2-affected Samoyeds, the mutation is a 1,267-bp deletion in the 5 0 end of the gene. This deletion removes exon 1 entirely and is predicted to remove the entire COL9A2 protein. RNA expression analysis suggests that none of the protein would be expressed due to RNA degradation, probably due to the activation of nonsense-mediated decay.
Although attempts to amplify the 5 0 UTR of COL9A2 cDNA failed, sequence analysis of the corresponding genomic region revealed several promoter elements in the normal chromosome. Sp1 elements (GGGCGG) are located at -153, -326, and -607 bp upstream to the ATG. A TATA box is located at -975 bp upstream from the ATG start codon. These elements are missing from the affected chromosome and yet the mutated COL9A2 mRNA is still expressed at least sufficiently enough to allow amplification by RT-PCR. This suggests that a different upstream promoter region is active in affected chromosomes. A TATA box at -1,287 and -1409 bp upstream to the ATG and a CCAAT-enhancer binding site at -1,402 bp are recognizable and are not deleted from the affected chromosome. RT-PCR with forward primers located immediately 5 0 to the deletion and reverse primers located on several of the exons shows positive transcripts (data not shown). Thus, these upstream TATA boxes may be alternatively activated in affected chromosomes. Since very weak expression is observed at the RNA level, it might be that the alternative promoter is not regulated or that those mRNA molecules are degraded very quickly by nonsense-mediated decay.
In humans, a recessive form of Stickler syndrome has been reported in a family with a nonsense mutation (R295X) in exon 9 of COL9A1 (Van Camp et al. 2006) . It is postulated that collagen IX is absent in affected members of this family. These patients had ophthalmologic findings that differed from those affected with the more usual autosomal dominant form of Stickler syndrome. Affected patients had degenerative vitreous changes, including progressive gel liquefaction that resembled those in aged eyes. This is similar to the ophthalmologic findings in the affected Labrador retrievers and Samoyeds, although the abnormalities are much more severe in homozygous dogs. The R295X-affected members also showed a moderate-tosevere hearing impairment, with a mildly down-sloping audiogram. In OSD-affected Labrador and samoyed dogs, no obvious signs of hearing impairment has been recognized, although specific quantitative hearing tests have not yet been undertaken. Nevertheless, these canine diseases provide valuable models for Stickler syndrome in its recessive mode.
Dogs homozygous for either drd1 or drd2 can usually be recognized upon physical examination by an experienced veterinarian, particularly an experienced veterinary ophthalmologist or an experienced veterinary orthopedist, and sometimes by experienced dog breeders. However, recognition of affected dogs is not sufficient to allow adequate selection pressure to be applied to significantly reduce the gene frequency of the mutation in the population. It has been widely held that dogs heterozygous for either drd1 or drd2 can usually be recognized upon physical examination by the presence of retinal folds or retinal dysplasia. However, we find no evidence to support this hypothesis in the Labrador retriever breed. Although one Labrador retriever dog with an ophthalmoscopically diagnosed retinal fold was genotyped heterozygous for the COL9A3 mutation, 21 with retinal folds were wild-type normal at the locus (Supplementary Table 2A ). Moreover, seven dogs that were phenotypically normal were genotyped heterozygous for the mutation. A Fisher exact test failed to reject the null hypothesis of independence.
It also should be noted that several purebred Labrador retrievers, diagnosed clinically as affected with short-limbed dwarfism, were found to be homozygous normal when tested for the COL9A3 mutation (n = 3). These findings suggest that at least in Labrador retrievers there are likely to be further mutations yet to be found that account for phenotypes that include retinal folds and/or dwarfisms. These findings emphasize the need for molecular genetic testing to obtain accurate genotypes of these dogs.
These OSD canine models can be used to further evaluate the relationships between the COL9 alpha chains A1, A2, and A3, their regulatory mechanism, and their effect on folds and vitreal structure in the eye, as well as future treatment possibilities including, potentially, gene therapy.
